American Biogenetics acquires Stellar :
This article was originally published in Clinica
American Biogenetic Sciences has bought Stellar Bio Systems in a staged payment deal that could total around $1.4 million in stock and cash. According to ABS, the acquisition will bring it access to new distribution channels for ABS' Thrombus Precursor Protein (tpP) and Functional Intact Fibrinogen (FiF) diagnostic tests. It will also provide its own immunodiagnostic test menu and Antigen Free technology, to produce monoclonal antibodies unattainable by conventional means. ABS will make an initial payment of $700,000 in stock and $120,000 in cash with milestone payments over the next three years.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.